Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers

Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.

Trial Details

NCT ID
NCT07864701
Phase
PHASE1 / PHASE2
Sponsor
Chengdu Anticancer Bioscience, Ltd.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • JMBI-001 Tablets
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Able to fully understand the study requirements, voluntarily agree to participate in the study, and provide written informed consent.
  • Male or female participants aged 18 to 75 years, inclusive.
  • Histologically or cytologically confirmed malignant tumor. Participants with solid tumors must have unresectable locally advanced or metastatic dis…
  • Phase Ia dose-escalation stage: Solid tumors, including but not limited to gastric cancer, colorectal cancer, non-small cell lung cancer, hepatocel…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →